BioLineRx is a small Israeli biopharmaceutical company focused on in-licensing early-stage oncology and rare disease drug candidates, advancing them through clinical development, and then out-licensing commercialization rights to partners in exchange for upfront payments, milestones, and royalties. BioLineRx's only approved product is APHEXDA (motixafortide), an injectable CXCR4 inhibitor used with G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma patients. APHEXDA is commercialized by partners: Ayrmid Pharma holds global rights outside Asia, and Gloria holds Asian rights. BioLineRx earns tiered royalties of 18–23% on net sales from Ayrmid, plus potential commercial milestones of up to $87M, while Gloria offers up to $246M in combined development and sales milestones. BioLineRx retains rights to develop motixafortide in solid tumors, and is co-funding (alongside Regeneron) a Phase 2b trial combining motixafortide with Regeneron's PD-1 inhibitor cemiplimab and chemotherapy in first-line metastatic pancreatic cancer, with a futility analysis planned for 2026. The company's other core pipeline asset is GLIX1, a first-in-class oral small molecule that restores TET2 enzyme activity to trigger DNA damage in cancer cells. GLIX1 is being developed through a joint venture with Norwegian biotech Hemispherian, initially targeting glioblastoma, with a Phase 1/2a trial expected to start in Q1 2026. BioLineRx's cost structure is lean following the 2024 Ayrmid deal, which allowed it to shut down U.S. commercial operations, reducing annual operating cash burn to roughly $12M.